M. Ankersen

发表

Recognition of privileged structures by G-protein coupled receptors.

Robert P Bywater, R. Bywater, K. Bondensgaard, 2004, Journal of medicinal chemistry.

Daily low-dose administration of growth hormone secretagogue stimulates pulsatile growth hormone secretion and elevates plasma insulin-like growth factor-1 levels in pigs

J. Veldhuis, M. Ankersen, P. Johansen, 2007, Endocrine.

Ipamorelin, the first selective growth hormone secretagogue.

K. Raun, K. Madsen, H. Thøgersen, 1998, European journal of endocrinology.

Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study

T. Blevins, Y. Raiter, A. Barve, 2018, Diabetes, obesity & metabolism.

Adenosine is an agonist of the growth hormone secretagogue receptor.

L. Thim, M. Ankersen, B. S. Hansen, 2000, Endocrinology.

Efficacy and safety of MYL‐1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study

T. Blevins, A. Barve, M. Ankersen, 2018, Diabetes, obesity & metabolism.

Serendipitous discovery of a new class of agonists for the melanocortin 1 and 4 receptors and a new class of cyclophanes.

K. Conde-Frieboes, K. Raun, H. Thøgersen, 2011, Bioorganic & medicinal chemistry letters.

Nonpeptide somatostatin agonists with sst4 selectivity: synthesis and structure-activity relationships of thioureas.

C. Tang, C. Stidsen, A. Crider, 1998, Journal of medicinal chemistry.

Discovery of a Novel Non-Peptide Somatostatin Agonist with SST4 Selectivity

C. Stidsen, M. Ankersen, Shengquan Liu, 1998 .

Pharmacological characterisation of a new oral GH secretagogue, NN703.

K. Raun, T. Hansen, M. Ankersen, 1999, European journal of endocrinology.

Growth hormone secretagogues: discovery of small orally active molecules by peptidomimetic strategies.

M. Ankersen, 2002, Progress in medicinal chemistry.

Growth hormone secretagogues derived from NN703 with hydrazidesas c-terminal.

K. Raun, M. Ankersen, K. Kramer Nielsen, 2000, European journal of medicinal chemistry.

The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency.

K. Raun, T. Hansen, M. Ankersen, 2002, European journal of medicinal chemistry.

Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin.

K. Raun, T. Hansen, M. Ankersen, 2001, Bioorganic & medicinal chemistry letters.

New highly potent dipeptidic growth hormone secretagogues with low molecular weight.

K. Raun, T. Hansen, M. Ankersen, 2000, European journal of medicinal chemistry.

A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.

K. Raun, K. Madsen, H. Thøgersen, 1998, Journal of medicinal chemistry.

Investigation of Bioisosteres of the Growth Hormone Secretagogue L‐692, 429.

T. Hansen, M. Ankersen, B. S. Hansen, 1997 .

INVESTIGATION OF BIOISOSTERS OF THE GROWTH HORMONE SECRETAGOGUE L-692,429.

T. Hansen, M. Ankersen, B. S. Hansen, 1997 .

Parallel solid-phase synthesis of disubstituted (5-biphenyltetrazolyl) hydantoins and thiohydantoins targeting the growth hormone secretagogue receptor.

K. Bondensgaard, M. Ankersen, B. S. Hansen, 2004, Bioorganic & medicinal chemistry letters.

Aspirin prodrugs: synthesis and hydrolysis of 2-benzyloxy-2-methyl-4H-1,3-benzodioxin-4-ones.

M. Ankersen, A. Senning, 1989, Acta chemica Scandinavica.

Synthesis, properties and prodrug potential of 2-methyl-2-oxy- and 2-methyl-2-thio-4H-1,3-benzodioxin-4-ones.

M. Ankersen, A. Senning, K. Nielsen, 1989, Acta chemica Scandinavica.

Nonpeptide Somatostatin Agonists with sst4 Selectivity: Synthesis and Structure—Activity Relationships of Thioureas.

C. Stidsen, A. Crider, M. Ankersen, 1999 .

PREPARATION OF SYMMETRICAL SUBSTITUTED DIPHENYL DISELENIDES

S. Wilson, M. Ankersen, 1994 .

Kinetics of degradation of 4-imidazolidinone prodrug types obtained from reacting prilocaine with formaldehyde and acetaldehyde.

S. Larsen, C. Larsen, M. Ankersen, 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Kinetics of degradation and oil solubility of ester prodrugs of a model dipeptide (Gly-Phe).

S. Larsen, C. Larsen, Susan Weng Larsen, 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

High constitutive signaling of the ghrelin receptor--identification of a potent inverse agonist.

T. Schwartz, B. Holst, M. Ankersen, 2003, Molecular endocrinology.

Physicochemical characteristics and in vitro release from oil-based vehicles of peptidomimetics: parenteral depots for intra-articular administration

S. Larsen, C. Larsen, J. Østergaard, 2011, Drug development and industrial pharmacy.

Serendipitous discovery of a new class of agonists for the melanocortin 1 and 4 receptors and a new class of cyclophanes.

K. Conde-Frieboes, K. Raun, H. Thøgersen, 2011, Bioorganic & medicinal chemistry letters.